Metformin Sandoz

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformin Sandoz (Metformin Hydrochloride)

Q: What is Metformin Sandoz used for?

Metformin Sandoz is a prescription‑only oral medication indicated for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose by improving insulin sensitivity and reducing hepatic glucose production, thereby supporting better glycaemic control in adult patients.

Q: How does Metformin Hydrochloride work?

Metformin Hydrochloride acts primarily by inhibiting the liver’s production of glucose (gluconeogenesis) and by increasing the sensitivity of muscle and fat cells to insulin. This dual action reduces the amount of glucose released into the bloodstream and enhances peripheral glucose uptake.

Q: What is the usual dose of Metformin Sandoz?

The appropriate dose of Metformin Sandoz is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made during treatment to achieve optimal blood‑glucose targets.

Q: Is Metformin Sandoz safe during pregnancy or breastfeeding?

Safety data for Metformin Sandoz in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is deemed necessary, close monitoring of both mother and infant is recommended.

Q: How do I order Metformin Sandoz from GNH India?

To request Metformin Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Q: How does Metformin Sandoz compare with other antidiabetic drugs?

Metformin Sandoz belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors or insulin in its mechanism of reducing hepatic glucose output and improving insulin sensitivity. It is generally weight‑neutral, has a low risk of hypoglycemia when used alone, and is often recommended as first‑line therapy for type 2 diabetes.

Q: How should Metformin Sandoz be stored?

Metformin Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability throughout its shelf life.

Q: How is Metformin Sandoz administered?

Metformin Sandoz is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Metformin Sandoz?

The most serious potential risk is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast agents. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain or unexplained fatigue develop.

Q: Who should not use Metformin Sandoz?

Metformin Sandoz is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in patients who have experienced lactic acidosis while on metformin therapy.

Metformin Hydrochloride, the active ingredient in Metformin Sandoz, is a biguanide presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels by improving the body’s response to insulin.

GNH India supplies Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU quality standards and regulatory requirements. The product conforms to European Union pharmacopeial specifications.

Manufacturer / TM Owner

1a Farma A/S

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformin Sandoz is an oral biguanide used to improve glycemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
Prediabetes (impaired glucose tolerance): delays progression to type 2 diabetes.
Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

How It Works

Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis, decreasing the liver’s production of glucose. It also enhances peripheral insulin sensitivity, promoting increased glucose uptake by muscle and adipose tissue, and modestly reduces intestinal absorption of glucose, collectively contributing to lower blood glucose concentrations.

Side Effects

Metformin Sandoz may cause a range of adverse reactions, most of which are related to the gastrointestinal tract or metabolic disturbances.

Common Side Effects

Nausea: mild to moderate stomach upset.
Diarrhea: frequent loose stools.
Abdominal discomfort: cramps or pain.
Metallic taste: transient alteration of taste.
Loss of appetite: reduced desire to eat.
Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

Lactic acidosis: rare but potentially fatal buildup of lactate.
Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Hepatic failure: signs of liver dysfunction.
Hypoglycemia: when combined with other glucose‑lowering agents.
Vitamin B12 deficiency: long‑term use may reduce B12 levels.

Precautions & Warnings

When prescribing Metformin Sandoz, clinicians should consider several safety factors to minimize risk.

Renal function: avoid in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²).
Hepatic function: use cautiously in patients with liver disease.
Lactic acidosis risk: discontinue before surgeries or radiologic contrast studies.
Pregnancy and lactation: assess benefit‑risk as safety data are limited.
Drug monitoring: check renal function and blood glucose regularly.
Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Metformin Sandoz can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Iodinated contrast agents: increase risk of acute kidney injury and lactic acidosis.
Alcohol: may potentiate lactic acidosis.
Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

ACE inhibitors or ARBs: monitor renal function and potassium.
Loop or thiazide diuretics: may affect renal clearance of metformin.
Other antidiabetic agents (e.g., sulfonylureas, insulin): increase risk of hypoglycemia.
Beta‑blockers: may mask hypoglycemia symptoms.

Frequently Asked Questions

Metformin Sandoz is a prescription‑only oral medication indicated for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose by improving insulin sensitivity and reducing hepatic glucose production, thereby supporting better glycaemic control in adult patients.

Metformin Hydrochloride acts primarily by inhibiting the liver’s production of glucose (gluconeogenesis) and by increasing the sensitivity of muscle and fat cells to insulin. This dual action reduces the amount of glucose released into the bloodstream and enhances peripheral glucose uptake.

The appropriate dose of Metformin Sandoz is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made during treatment to achieve optimal blood‑glucose targets.

Safety data for Metformin Sandoz in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is deemed necessary, close monitoring of both mother and infant is recommended.

To request Metformin Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metformin Sandoz belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors or insulin in its mechanism of reducing hepatic glucose output and improving insulin sensitivity. It is generally weight‑neutral, has a low risk of hypoglycemia when used alone, and is often recommended as first‑line therapy for type 2 diabetes.

Metformin Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability throughout its shelf life.

Metformin Sandoz is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

The most serious potential risk is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal or hepatic impairment, or after exposure to iodinated contrast agents. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain or unexplained fatigue develop.

Metformin Sandoz is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in patients who have experienced lactic acidosis while on metformin therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.